 |
| Agilent Diagnostics and Genomics President Jacob Thaysen |
Dako is extending its collaboration with pharma giant Amgen ($AMGN) to develop a companion diagnostic for an unnamed Amgen cancer drug. Neither side is revealing financial details, but Dako, now an Agilent company, said the deal will focus on personalized medicine and tests that pair patients with suitable treatments. The collaboration builds on agreements from 2012, when Dako first inked a deal with the company to develop companion diagnostics for cancer meds. "We are proud to both continue and broaden our multi-year partnership with Amgen," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group. "Together we will continue our work in the development of high-quality companion diagnostic products to enable physicians and pathologists to identify cancer patients who are more likely to respond to a specific therapy." Release